You searched for "blindness"

783 results found

Intravitreal aflibercept for retinal angiomatous proliferation (RAP)

In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...

Results of fixed aflibercept treatment regime in type 3 neovascularisation

In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...

VIBIM Study: One-year results of treatment of DME with aflibercept using TnE

The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...

Microvasculature changes of mCNV after ranibizumab treatment using OCTA

In this study the authors aim to evaluate the vascular changes of myopic choroidal neovascularisation (mCNV) after ranibizumab treatment using optical coherence tomography-angiography (OCTA). The 3×3 OCTA en face images were analysed for the absence / presence of mCNV, CNV...

Rebound phenomenon after IVT triamcinolone acetonide for macular oedema

In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...

Sickle cell maculopathy

This paper reports the result of a prospective study to analyse the prevalence of sickle cell maculopathy (SCM) and its associations with age, sex, genotype, proliferative sickle cell retinopathy (PSR) stage, and the impact on visual acuity (VA). This study...

Insights in resistant diabetic macular oedema

This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...

Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders

This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...

OCTA in geographic atrophy

In this article the authors aim to give an overview of the current literature concerning the application of OCT-A in geographic atrophy (GA). GA is a disease characterised by loss of outer retinal layers including photoreceptors, degeneration of the retinal...

Ripasudil after Descemet stripping in Fuch’s endothelial dystrophy

This study prospectively evaluated the use of ripasudil, a rho kinase inhibitor, in patients undergoing Descemet’s stripping only (DSO) without an endothelial graft for Fuch’s endothelial dystrophy (FED). Patients with dense central guttae limited to the central 5mm of the...

How long to air tamponade after DMEK?

This interventional case series looked at the influence of different intraoperative air tamponade times on graft adherence after descemet membrane endothelial keratoplasty (DMEK). A total of 117 eyes with Fuchs endothelial corneal dystrophy (FECD) that underwent DMEK were included. Patients...